published June 4, 2026
Welcome to the April 2026 Lymphoma Australia Health Professionals Newsletter
published June 4, 2026
Welcome to the June 2026 Lymphoma Australia Community Newsletter Inside this edition we cover the foll
published June 4, 2026
Welcome to the April 2026 Lymphoma Australia Community Newsletter Inside this edition w
published June 4, 2026
Welcome to the March 2026 Lymphoma Australia Community Newsletter Inside this edition we cover the followin
published June 4, 2026
Welcome to the February 2026 Lymphoma Australia Newsletter Inside this edition we cover the following topics:
published April 1, 2026
Now listed on the PBS From 1st April 2026, Mogalizumab (brand name POTELIGEO®) will be available on the
published April 1, 2026
Now listed on the PBS As of 1st March 2026, Glofitamab (brand name COLUMVI®) is now listed on the PBS i
published March 25, 2026
Now listed on the PBS As of 1st May 2025, Epcoritamab is listed on the Pharmaceutical Benefit Scheme (PBS)
published March 14, 2026
Welcome to the December 2025 Lymphoma Australia Health Professionals Newsletter Inside this edition we cover
published March 14, 2026
Welcome to the February 2026 Lymphoma Australia Newsletter Inside this edition we cover the following topics:
published March 14, 2026
Welcome to the December 2025 Lymphoma Australia Newsletter Inside this edition we cover the following topics:
published October 15, 2025
Welcome to our October 2025 Health Professional Newsletter In this edition we cover: National

Contact Lymphoma Australia Today!

Please note:
Lymphoma Australia staff are only able to reply to emails sent in English language.

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.